El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Charles River Laboratories International Inc
Cerrado
SectorSalud
176.76 1.37
Resumen
Variación precio
24h
Mínimo
167.92
Máximo
178.05
Ingresos | -332M -277M |
|---|---|
Ventas | -11M 994M |
BPA | 2.43 |
Margen de beneficio | -27.816 |
Empleados | 18,300 |
EBITDA | 730K 198M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +17.1% upside |
Próximas Ganancias | 6 may 2026 |
|---|
Capitalización de Mercado | 852M 8.8B |
|---|---|
Apertura anterior | 175.39 |
Cierre anterior | 176.76 |
Noticias sobre sentimiento de mercado
By Acuity
23%
77%
37 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Strong Bullish Evidence
Charles River Laboratories International Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Charles River Laboratories International Inc Esperado
Precio Objetivo
By TipRanks
17.1% repunte
Estimación a 12 meses
Media 204.3 USD 17.1%
Máximo 265 USD
Mínimo 175 USD
De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Charles River Laboratories International Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
37 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Coyuntura alcista notoria
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Charles River Laboratories International Inc
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Live chat